key: cord-0699790-c1umbrjq
authors: de la Fuente, José; Armas, Octavio; Sánchez‐Rodríguez, Luis; Gortázar, Christian; Lukashev, Alexander N.
title: Citizen science initiative points at childhood BCG vaccination as a risk factor for COVID‐19
date: 2021-04-20
journal: Transbound Emerg Dis
DOI: 10.1111/tbed.14097
sha: e3f58b442e697a7cfd93ca5b090d29259dd54479
doc_id: 699790
cord_uid: c1umbrjq

Current results do not provide conclusive evidence on the effect of BCG vaccination on COVID‐19 alone or in combination with other factors. To address this limitation, in this study we used a citizen science initiative on the COVID‐19 pandemic to collect data worldwide during 2 October 2020–30 October 2020 (1,233 individuals) in a structured way for analysing factors and characteristics of affected individuals in relation to BCG vaccination. For the first time, the results of our study suggested that vaccination with BCG may increase the risk for COVID‐19 at certain age, particularly in individuals vaccinated at childhood. Childhood BCG vaccination increased the likelihood of being diagnosed with COVID‐19 fivefold in COVID‐19 low‐incidence countries and threefold in high‐incidence countries. A reasonable explanation for this effect is the activation of certain innate immunity mechanisms associated with inflammatory reactions. These factors should be considered when analysing the risks associated with this global pandemic.

The pandemic of coronavirus disease 19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a health, social, economic and scientific challenge. Early identification of risk factors for COVID-19 disease morbidity and mortality is necessary during the pandemic to develop treatment strategies and interventions with priority for those at highest risk. Citizen science plays a key role in addressing these challenges trough monitoring, assessment and control of COVID-19 (Pearse, 2020) .

The Bacille Calmette-Guérin (BCG) vaccine against tuberculosis has been associated with non-specific pleiotropic protective effects against other infections, and significant reductions in allcause morbidity and mortality (Escobar et al. 2020; Giamarellos-Bourboulis et al., 2020) . In vaccinology, challenging questions remain regarding the still unknown processes through which vaccines activate or not the innate immunity (Platt & Wetzler, 2013) .

Regarding COVID-19, it has been proposed that trained innate immunity or heterologous T-cell responses induced by BCG vaccination may reduce disease incidence, morbidity and severity (Curtis et al., 2020; Giamarellos-Bourboulis et al., 2020; Jirjees et al., 2020; Kubota et al., 2020; Levi et al., 2021; Mantovani & Netea, 2020; Marín-Hernández et al., 2021; Pana et al., 2021; Wickramasinghe et al., 2020) . However, considering the limitations of ecological studies, analyses of the links between BCG vaccination and COVID-19 incidence and mortality have shown no correlation (Hensel et al., 2020; Liu et al., 2021; Ricco & Ranzieri, 2021) , negative correlation (Goswami et al., 2021; Singh et al., 2020) or changes in correlation patterns as the pandemic progresses (Kubota et al., 2020) . Other factors that have been proposed to affect SARS-CoV-2 infection and disease morbidity and mortality include ABO blood group (higher and lower susceptibility to infection in individuals with A and O blood groups, respectively) (Hodžić et al., 2020; Wu et al., 2020) , age (older age associated with COVID-19 severity and mortality) (Ho et al., 2020) , antibody levels against glycan Galα1-3Galβ1-(3)4GlcNAc-R (α-Gal) present in midgut microbiota (lower antibody levels associated with higher disease severity) (Urra et al., 2020) and sex (male patients appear to be at higher risk of mortality) (Ritter & Kararigas, 2020) .

Some evidence also suggests a higher COVID-19 susceptibility among BCG-vaccinated individuals. Recently, a COVID-19 outbreak occurred among crew members of the U.S.S. Theodore

Roosevelt. Infection spread quickly in this group of predominantly young males (mean age 27 years), because transmission was facilitated by close-quarters conditions. In total, 26.6% of the crew (1,271 of 4,479) tested positive for SARS-CoV-2 infection by PCR. Nearly half of those who tested positive for the virus never had symptoms, 23 (1.7%) were hospitalized, 4 (0.3%) received intensive care and 1 died (Kasper et al., 2020) . This represents a very low hospitalization rate. Vaccination with BCG is not officially recommended in the U.S.A. (BCG Vaccine, 2020) and is not part of routine navy healthcare (https://www.med.

navy.mil/direc tives/ Exter nalDi recti ves/6224.8C.pdf). By contrast, a study on COVID-19-associated hospitalizations among U.S. healthcare personnel, a group where BCG vaccination was considered on an individual basis (BCG Vaccine, 2020), found that 27.5% (i.e. 100 times more) received intensive care (Kambhampati et al., 2020) .

These results do not provide conclusive evidence on the effect of BCG vaccination on COVID-19 alone or in combination with other factors. To address this limitation, in this study we used a citizen science initiative on the COVID-19 pandemic to collect data in a structured way for analysing factors and characteristics of affected individuals in relation to BCG vaccination.

A questionnaire was conducted during 2 October 2020-30 October 2020 containing 10 qualitative questions (sex, blood group, country of residence, BCG vaccination, COVID-19 diagnostic, hospitalization with COVID-19, PCR test, antibody test, symptomatic and consent), two quantitative questions (age, duration of symptoms) and one space for free text (symptoms description) (total 13 questions) was circulated via e-mail and social networks (i.e. Twitter, LinkedIn). Relative to BCG vaccination and COVID-19, the following seven questions were included in the survey (Table 1) cases per 100,000 inhabitants (>1,000 or <1,000, calculated after data downloaded from the ECDC at https://www.ecdc.europa.eu/ en/publi catio ns-data/downl oad-today s-data-geogr aphic -distr ibuti on-covid -19-cases -world wide, accessed on 02 November 2020); 

The significant effects resulting from the backward selection of the model were age, BCG vaccination and COVID-19 cases per 100,000

inhabitants, which influence the likelihood of being diagnosed with COVID-19 (Table 2) . Sex, blood group and region were not retained by the model. Childhood BCG vaccination increased the likelihood of being diagnosed with COVID-19 fivefold in COVID-19 low-incidence countries and threefold in high-incidence countries (Figure 1 ).

Moreover, BCG-vaccinated subjects were three times more likely to have a positive SARS-CoV-2 PCR or blood test (p <.0001) and

were also seven times more likely to have been hospitalized due to COVID-19 (p <.0001). However, BCG vaccination had no effect on symptoms development nor on symptoms duration (p >.05).

The results of our study suggested that BCG vaccination constitutes a risk factor for COVID-19 and raised the question of why is BCG vaccination not only not protective but increases disease risk?

Children are usually vaccinated with a number of adjuvantcontaining formulations, which may decrease their relative susceptibility to COVID-19 (Castagnoli et al., 2020) . Exposure to BCG can reprogram or train the innate immune system for trained immunitymediated response to secondary stimuli (Rusek et al., 2018) .

Nevertheless, based on current evidence, BCG vaccination during childhood does not protect against SARS-CoV-2 infection in adults, likely due to the limited long-lasting trained immunity induced by BCG and/or the probable abrogated effect of other vaccines (Hamiel et al., 2020) . In fact, as recently published (Mantovani & Netea, 2020) , myeloid cells (e.g. monocytes and dendritic cells) associated with the immune response to BCG have a relatively short life in the vascular system. However, recent results support a role for epigenetic reprogramming of bone marrow myeloid progenitor hematopoietic stem cells in the long-lasting trained innate immunity in response to BCG (Cirovic et al., 2020) .

Nevertheless, community BCG vaccination raises questions regarding the stimulation of innate immunity, which may be associated with stronger inflammatory reactions and pro-inflammatory cytokine levels associated with COVID-19 severity (Huang et al., 2020) . For example, when monocytes and natural killer cells F I G U R E 1 Effect of BCG vaccination on the probability of being diagnosed with COVID-19 in low-incidence and highincidence countries from BCG-vaccinated individuals are compared to non-vaccinated controls, they display higher expression levels of toll-like receptors and cytokines (e.g. Tumour Necrosis Factor alpha, TNFα and interleukin 6, IL-6) in response to various pathogens (Ifrim et al., 2014) . It has been shown that the infection with SARS-CoV-2 can potentially result in the 'cytokine storm syndrome (CSS)' (Horowitz et al., 2020) .

The CSS has been associated with the activation of the nuclear factor kappa B innate immune pathway resulting in the upregulation of pro-inflammatory cytokines such as TNFα, IL-1β, IL-6 and IL-8 (Horowitz et al., 2020) . Therefore, it is possible that particularly in adults after certain age and vaccinated during childhood the longlasting trained immunity mechanisms induced by BCG may result in CSS and thus increase risk of COVID-19.

The findings in this report are subject to at several limitations. Our questionnaire did not collect information on predisposing conditions other than country, age, sex or BCG vaccination, such as obesity, which is a known risk factor for COVID-19 (Kambhampati et al., 2020 

The authors thank responders to the survey and colleagues and relatives who assisted in the distribution of the survey-associated link.

We thank members of our laboratories and collaborators for fruitful discussions and acknowledge support of the University of Castilla La Mancha (UCLM, Spain) to COVID-19-related studies.

We declare no competing interests.

JF, OA, CG and ANL designed the study. JF, OA, LSR, CG and ANL contributed to the collection and management of the data. CG analysed the data. JF and CG interpreted the data and wrote the manu-

Group contributed to data collection and systematization. All authors revised the manuscript and approved the final version.

The authors confirm that the ethical policies of the journal, as noted on the journal's author guidelines page, have been adhered to. No ethical approval was required as this study was based on environmental RNA sampling. We used no individual patient data and performed no animal sampling. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

The data that support the findings of this study are available in the Supplementary Data.

José de la Fuente https://orcid.org/0000-0001-7383-9649

Christian Gortázar https://orcid.org/0000-0003-0012-4006

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: A systematic review

BCG vaccination in humans elicits trained immunity via the hematopoietic progenitor compartment

Considering BCG vaccination to reduce the impact of COVID-19

BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)

Activate: Randomized clinical trial of BCG vaccination against infection in the elderly

Endemic infections, vaccinations and variability of SARS-COV2 worldwide epidemiology: A cross-sectional study

SARS-CoV-2 rates in BCGvaccinated and unvaccinated young adults

Protection against SARS-CoV-2 by BCG vaccination is not supported by epidemiological analyses

Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants

COVID-19 in the developing world: Is the immune response to α-Gal an overlooked factor mitigating the severity of infection?

Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Trained immunity or tolerance: Opposing functional programs induced in human monocytes after engagement of various pattern recognition receptors

COVID-19 death and BCG vaccination programs worldwide. Tuberculosis and Respiratory Diseases

COVID-19-associated hospitalizations among health care personnel -COVID-NET, 13 States

An outbreak of Covid-19 on an aircraft carrier

Multiple drivers of the COVID-19 spread: The roles of climate, international mobility, and region-specific conditions

Letter in response to article in journal of infection: Impact of routine infant BCG vaccination on COVID-19

Association between vaccinations and clinical manifestations in children with COVID-19

Trained innate immunity, epigenetics, and Covid-19

Anticipated reduction in COVID-19 mortality due to population-wide BCG vaccination: Evidence from Germany

Country-level determinants of the severity of the first global wave of the COVID-19 pandemic: An ecological study

Deliberation, citizen science and Covid-19

Cross-immunization against respiratory coronaviruses may protect children from SARS-CoV2: More than a simple hypothesis? Frontiers in Pediatrics

Innate immunity and vaccines

BCG vaccination and COVID-19: Was flattening the curve just an illusion? Infectious Diseases Now

Sex-biased vulnerability of the heart to COVID-19

Infectious agents as stimuli of trained innate immunity

Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years

Trained immunity" from Mycobacterium spp. exposure or BCG vaccination and COVID-19 outcomes

The antibody response to the glycan α-Gal correlates with COVID-19 disease symptoms

WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination

Association between ABO blood groups and COVID-19 infection, severity and demise: A systematic review and meta-analysis

Additional supporting information may be found online in the Supporting Information section. How to cite this article: de la Fuente